These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17407369)

  • 21. Lisdexamfetamine: a prodrug stimulant for ADHD.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Aug; 46(8):19-22. PubMed ID: 18777964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.
    Wigal SB; Raja P; Shukla A
    Expert Opin Pharmacother; 2013 Jan; 14(1):137-45. PubMed ID: 23241144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amphetamine, past and present--a pharmacological and clinical perspective.
    Heal DJ; Smith SL; Gosden J; Nutt DJ
    J Psychopharmacol; 2013 Jun; 27(6):479-96. PubMed ID: 23539642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attention-deficit/hyperactivity disorder: the road traveled and the road ahead.
    Jun A
    Am J Health Syst Pharm; 2009 Nov; 66(22):2003. PubMed ID: 19890082
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
    Brams M; Giblin J; Gasior M; Gao J; Wigal T
    Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate.
    Findling RL; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; DeLeon A; Ginsberg LD
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):28-35. PubMed ID: 23410139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of the safety of lisdexamfetamine dimesylate.
    Coghill DR; Caballero B; Sorooshian S; Civil R
    CNS Drugs; 2014 Jun; 28(6):497-511. PubMed ID: 24788672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Goodman DW; Kollins SH; Weisler RH; Krishnan S; Zhang Y; Biederman J;
    J Clin Psychiatry; 2008 Sep; 69(9):1364-73. PubMed ID: 19012818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(3):425-6, 428-30. PubMed ID: 17510042
    [No Abstract]   [Full Text] [Related]  

  • 33. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.
    Krishnan SM; Pennick M; Stark JG
    Clin Drug Investig; 2008; 28(12):745-55. PubMed ID: 18991468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.
    Turgay A; Ginsberg L; Sarkis E; Jain R; Adeyi B; Gao J; Dirks B; Babcock T; Scheckner B; Richards C; Lasser R; Findling RL
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):503-11. PubMed ID: 21186969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological properties and clinical effects of the ADHD drug, Lisdexamfetamine (Vyvanse
    Sakai C
    Nihon Yakurigaku Zasshi; 2020; 155(6):413-425. PubMed ID: 33132261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion.
    Faraone SV; Upadhyaya HP
    J Clin Psychiatry; 2007 Nov; 68(11):e28. PubMed ID: 18052554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD.
    Waxmonsky JG; Waschbusch DA; Glatt SJ; Faraone SV
    J Clin Psychiatry; 2011 Oct; 72(10):1366-75. PubMed ID: 21367347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.